Adlai Nortye is a clinical-stage biotechnology company focused on discovering and developing cancer therapies. It maintains dual R&D operations in the United States and China and builds a pipeline around RAS-targeted agents and next-generation immuno-oncology candidates. Programs include oral pan-RAS inhibitors, antibody–drug conjugates, and novel immune modulators aimed at hard-to-treat solid tumors.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 0 | — | -58.8 | — |
| 2023 | 0 | — | -109.2 | — |
| 2024 | 0 | — | -51.9 | — |
| 2025 | 5 | — | -35.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Olema Pharmaceuticals, Inc. (OLMA), Rapid7, Inc. (RPD), UP Fintech Holding Limited (TIGR), Ramaco Resources, Inc. (METC), iQIYI, Inc. (IQ), Beta Bionics, Inc. (BBNX)